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Abstract
Eight cholesterol based cationic lipids differing in the headgroup have been synthesized based on the ether linkage between the cationic
headgroup and the cholesterol backbone. All the lipids formed stable suspensions in water. Transfection efficacies were examined in the absence
and presence of serum using their optimized liposomal (lipid:DOPE) formulations. Our results showed that the transfection activities depend on
the nature of the headgroup. Lipid bearing 4-N,N′-dimethylaminopyridine (DMAP) as headgroup showed the maximum transfection efficacy in
the presence of serum. Importantly, the optimized formulation for this cationic lipid does not require DOPE, which is being used by most
commercially available formulations. Cytotoxicity studies showed that the introduction of the positive charge decreases the cell viability of the
cationic lipid formulations. Gel electrophoresis and Ethidium bromide exclusion assay revealed the different DNA binding abilities of
formulations depending upon the headgroup of the cholesteryl lipid.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cationic lipid; Liposome; Gene transfection; Serum1. Introduction
Gene therapy, the delivery of DNA encoding a therapeutic
gene of interest to the target cells or organs with consequent
expression of the transgene provides new hope for curing various
genetic diseases [1–3]. Completion of the human genome project
has given wealth of information to make the gene therapy a viable
strategy. Development in various molecular biology techniques
have given the opportunity to scientists to manipulate the viruses
to make them impressive carriers for gene delivery [4]. But theAbbreviations: DC-Chol, 3β-[N,(N,N-dimethylaminoethane)-carbamoyl]
cholesterol; DOPE, 1,2-dioleoyl-L-α-glycero-3-phosphatidylethanolamine;
DOTMA, N-[1-(2,3-dioleyloxy)propane]-N,N,N-trimethylammonium chloride;
DOTAP, N-[1-(2,3-dioleoyloxy)propane]-N,N,N-trimethylammonium chloride;
MFI, mean fluorescence intensity; FACS, Fluorescence activated cell sorting
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doi:10.1016/j.bbamem.2007.12.010strong immunogenic response created by these viral vectors and
the risk of insertional mutagenesis limits the use of viral vectors
for clinical trials [5–7].
In recent years, there is an upsurge in the design of non-viral
vectors synthesized by chemical means. Various synthetic vectors
such as cationic lipids, [8] polymers, [9] lipopolymers, [10–13]
gemini surfactants, [14] gemini lipids [15,16] etc. have been
developed for the delivery of nucleic acids to mammalian cells
[17]. These synthetic vectors possess the advantages of easy
synthesis, high DNA carrying capacity, very low immunogenic
responses and less toxicity as compared to their viral counterparts
[18–30]. Felgner et al. in 1987 developed for the first time a
cationic lipid, DOTMA, for the delivery of genes intomammalian
cells, [31] which is used as co-liposomal formulation with DOPE.
Cationic lipids have since then been primarily constructed from
two types of hydrophobic segments. In DOTMA, two long
hydrocarbon chains have been used as its hydrophobic part. Later
on DC-Chol was developed as a new lipid for gene transfection
which is based on a cholesterol backbone [32]. Thereafter, various
modifications of lipid architectures were introduced at the
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the hydrophobic domains [33–35]. Nakanishi reported a novel
cationic cholesterol derivative with a hydroxyethyl amino
headgroup. This was found to be one of the most effective
among various derivatives of cationic cholesterol based lipids
[36]. These modifications at molecular level of the lipids
modulate their aggregation properties, which further determines
their transfection activities [17,37–47]. Therefore, the molecular
structure of cationic lipids is an important parameter that con-
trols their DNA complexation and gene transfection activity. The
functional group that links the polar head group with the hy-
drocarbon chains of such lipid molecules also plays a crucial role
in their utilization in gene transfer events. Thus, DOTMA, which
contains an ether linkage between the headgroup and the long
alkyl chains show greater in vivo transfection efficiency than
the corresponding ester analogue DOTAP [48,49]. Effect of the
headgroup variation of cationic lipids on transfection activity
have been investigated as well [50,51].
Cholesterol interaction with cationic lipid components in
membranes show differential behavior depending on the nature
of linkages in the lipid molecule [52]. We also reported the
design of three cholesterol based cationic lipids possessing
ammonium headgroups where different types of linkages were
used between the headgroup and the cholesterol backbone
(Fig. 1) [53,54]. Enhanced gene transfection activities were
recorded when the cationic ammonium headgroup was
appended to the cholesterol backbone using an ether linkage
as compared to its ester or urethane counterparts. However, the
effects of head group variation in the ether linked cholesteryl
lipids have not been examined so far. To optimize the structure-
activity relationship of such series of gene delivery agents
further, the influence of the head group characteristics of the
ether linked cholesterol lipids on physical chemical properties
of the lipoplexes and their relationship to cellular gene transfer
are required.
Accordingly, in the present investigation, we have synthe-
sized eight new cationic lipids based on ether linkage between
the positively charged headgroup and the cholesterol backbone.
Here, we varied the cationic headgroup from trimethylammoniumFig. 1. Molecular structures of cholesterol based cationic lipids based on different
linkages between the ammonium headgroup and the cholesterol backbone.to various other groups like 4, 4′-dimethylamino pyridinium
(DMAP), pyridinium, morpholinium, N-methylpiperizinium,
monoquaternized 1,4-diazabicyclo[2.2.2]octane (DABCO),
N-methyl pyrolidinium (NMP) (Fig. 2). A new lipid possessing
tertiary amine based N-methyl piperazine headgroup on a choles-
terol system was also prepared. All the new lipids formed stable
aqueous suspensions in water. The lipid suspensions were
characterized by dynamic light scattering (DLS). Then these
lipids were utilized for their gene transfection activity. We
prepared mixed lipid:DOPE liposomal formulations and opti-
mized their lipid:DOPE ratios at which maximum transfection
activities were achieved. The lipid Chol–DMAP showed
maximum transfection activities in the absence of DOPEwhereas
for the other lipid formulations, maximum gene transfer was
observed with 1:1 lipid:DOPE formulations. Resulting mixed
liposomes were characterized by dynamic light scattering. Then
using optimized lipid:DOPE formulations, we studied the
transfection activities mediated by these lipids in HeLa cells at
different N/P ratios. We also investigated the transfection
efficacies of these cationic lipids in the presence of 10% serum.
Gel electrophoresis and Ethidium bromide exclusion assay
lipoplexes using optimized lipid:DOPE ratios revealed different
binding abilities depending upon their headgroup structure.2. Materials and methods
All reagents, solvents and chemicals used in this study were of the highest
purity available. The solvents were dried prior to use. Column chromatography
was performed using 60–120 mesh silica gel. NMR spectra were recorded using
Jeol JNM λ-300 (300 MHz for 1H) spectrometer. The chemical shifts (δ) are
reported in ppm downfield from the internal standard; TMS, for 1H-NMR. Mass
spectra were recorded on a Kratos PCKompact SEQ V1.2.2 MALDI-TOF spec-
trometer or on a MicroMass ESI-TOF spectrometer or Shimadzu table-top GC–
MS or ESI–MS (HP1100LC-MSD). Infrared (IR) spectra were recorded on a
Jasco FT-IR 410 spectrometer using KBr pellets or neat. Cationic lipids were
synthesized as described below and were characterized fully by their 1H-NMR,
mass spectra and elemental analysis.
2.1. Synthesis
Cholest-5-en-3β-tosylate (2) [46]. To an ice-cooled solution of cholesterol (1)
(2.5 g, 6.47 mmol) in dry pyridine (5 ml) and dry chloroform (5 ml), p-tosyl
chloride (1.47 g, 7.76 mmol) was added. A catalytic amount of DMAP was also
added. The reaction mixture was then allowed to stir at 0 °C for 6 h. Solvent was
evaporated. Then, EtOAc (35 ml) was added, and the reaction mixture waswashed
with 1 N HCl (2×50 ml), water (50 ml), and brine (saturated NaCl) (50 ml); the
organic layer was separated and dried over anhydrous Na2SO4. The solvent was
evaporated to leave a residue. From the residue, cholest-5-en-3β-tosylate (2) was
recrystallized using chloroform andmethanol. Yield: white solid, 3.5 g, (6.5mmol,
90.0%). IR (neat) (cm−1): 2949, 2867, 1598, 1495, 1467, 1366, 1188, and 1174.
1H-NMR (CDCl3, 300 MHz): δ 0.65 (s, 3H), 0.84–2.29 (m, 41H), 2.44 (s, 3H),
4.32 (m, 1H), 5.30 (d, 1H, J=4.5 Hz), 7.31–7.34 (d, 2H, J=8.1 Hz), 7.78–7.81
(d, 2H, J=8.1 Hz).
Cholest-5-en-3β-oxyethane (3) [46]. Cholest-5-en-3β-tosylate (2) (3.5 g,
6.5 mmol) was taken in anhydrous dioxane. To this, dry ethylene glycol (10 g,
0.16 mol) was added, and the mixture was refluxed under nitrogen for 4 h. The
solution was cooled, and the solvent was removed under vacuum. A white
residue was obtained which was dissolved in ethyl acetate (50 ml) and washed
with water. The organic layer was separated, washed with NaHCO3 (50 ml),
water (50 ml), and brine (saturated NaCl) (50 ml), and dried over anhydrous
Na2SO4. Finally, the solvent was removed in vacuum and the product, cholest-5-
en-3β-oxyethane (3), was purified by column chromatography over silica gel
Fig. 2. Molecular structures of the cholesterol based cationic lipids based on different head groups possessing ether linkage between the headgroup and cholesterol
backbone synthesized and studied in this presentation.
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solid, 2.3 g, 5.3 mmol, 85%. IR (neat) (cm−1): 3438, 2936, 2868, 1466, and
1376. 1H-NMR (CDCl3, 300 MHz): δ 0.67 (s, 3H), 0.85–2.35 (m, 41H), 3.20
(m, 1H), 3.57–3.60 (t, 2H, J=6.0 Hz), 3.72 (t, 2H, J=6.0 Hz), 5.34 (d, 1H,
J=4.5 Hz). ESI–MS: 453 (M+Na+).
Cholest-5-en-3β-oxyethane tosylate (4) [46]. To an ice-cooled solution of
cholest-5-en-3β-oxyethan-2-ol (3) (2.2 g, 5.1 mmol) in dry pyridine (5 ml) and dry
chloroform (5 ml), p-tosyl chloride (1.16 g, 6.12 mmol) was added. The reaction
mixture was allowed to stir at 0 °C for 6 h. Solvent was removed. Then EtOAc
(40 ml) was added, and then the reaction mixture was washed with 1 N HCl
(2×50 ml), water (50 ml), and brine (saturated NaCl) (50 ml). Finally, the organic
layer was separated and dried over anhydrous Na2SO4. The solvent was removed
using a rotary evaporator, and the product, cholest-5-en-3β-oxyethane tosylate (4),
was purified by column chromatography over silica gel using a mixture of
petroleum ether and ethyl acetate [v/v=20:1]. Yield: 2.68 g, 7.04mmol, 90.0%. IR
(neat) (cm−1): 2935, 2886, 1598, 1465, 1360, 1189, and 1177. 1H-NMR (CDCl3,
300 MHz): δ 0.67(s, 3H), 0.85–2.25 (m, 41H), 2.44 (s,3H), 3.06–3.13 (m, 1H),
3.63–3.66 (t, 2H, J=6.0Hz), 4.13–4.16 (t, 2H, J=6.0 Hz), 5.31 (d, 1H, J=4.5 Hz),
7.32–7.35 (d, 2H, J=8.1 Hz), 7.79–7.82 (d, 2H, J=8.1 Hz). ESI–MS: 607.
Cholest-5-en-3β-oxyethane bromide (5) [54]. To a solution of cholest-5-en-
3β-oxyethane tosylate (4) (1.75 g, 3.54 mmol) in dry DMF, lithium bromide
(460 mg, 5.3 mmol) was added. The solution was refluxed under N2 atmosphere
at 70 °C for 7 h. Solvent was evaporated in vacuum. The crude product was
dissolved in ethyl acetate (50 ml) and the organic layer was washed first with
water (3×10 ml), and then with brine (saturated NaCl) (20 ml). Organic solvent
was evaporated to get a yellowish solid. The product, cholest-5-en-3β-oxyethane
bromide (5) was purified by column chromatography over silica gel using a
mixture of petroleum ether and ethyl acetate [v/v=20:1]. Yield: white so-
lid,1.23 g, 2.49 mmol, 82%. 1H-NMR (CDCl3, 300 MHz): δ 0.67 (s, 3H), 0.75–
1.51 (m, 34H), 1.69–1.96 (m, 5H), 2.12–2.32 (m, 2H), 3.15 (m, 1H), 3.35–3.39
(t, 2H, J=6.0 Hz), 3.69–3.73 (t, 2H, J=6.0 Hz), 5.33 (d, 1H, J=4.5 Hz).General method for the synthesis of cationic cholesteryl lipids
Cholest-5-en-3β-oxyethane bromide (5) (100 mg, 0.20 mmol) was taken in
dry MeOH: EtOAc (4 ml, v/v: 1/1) in a screw-top pressure tube. Appropriate
tertiary amine derivative was added to the solution and the solution was re-
fluxed for 48 h. Reaction mixture was cooled and solvent was evaporated. Crude
reaction mixture was then crystallized repeatedly from a mixture of MeOH:
EtOAc to afford a white solid compound in 80–90% yields. Purity of the product
was confirmed by TLC; the Rf ranged from 0.2–0.6 in 10:1 CHCl3/MeOH. All
the newly synthesized lipids were fully characterized by 1H-NMR, high reso-
lution mass spectrometry (HRMS), and C, H, N analysis. Pertinent analytical
and spectroscopic data are given below.
Chol–PYR. 1H-NMR (CDCl3, 300 MHz):δ 0.67 (s, 3H), 0.82–2.14 (m,
40H), 3.09 (m, 1H), 4.01 (s, 2H), 5.26 (s, 3H), 8.01–8.03 (m, 2H), 8.44 (m, 1H),
9.52–9.54 (m, 2H). HRMS (C34H54NO): Calcd. 492.7987; found 492.4301.
Anal. (C34H54NOBr.H2O) Calcd. C, 69.13; H, 9.56; N, 2.37; found. C, 69.06;
H, 9.68; N, 2.49.
Chol–MOR. 1H-NMR (CDCl3, 300 MHz):δ 0.64 (s, 3H), 0.82–2.28 (m,
40H), 3.18 (m, 1H), 3.59 (s, 3H), 3.74 (t, 2H), 3.87–4.01 (br. m, 8H), 4.23
(t, 2H), 5.32 (d, 1H, J=4.5 Hz). HRMS (C34H60NO2): Calcd 514.8457; found
514.4739. Anal. (C34H60NO2Br) Calcd. C, 68.66; H, 10.17; N, 2.36; found.
C, 68.71; H, 10.12; N, 2.49.
Chol–NMP. 1H-NMR (CDCl3, 300 MHz):δ 0.64 (s, 3H), 0.82–2.3 (m, 44H),
3.18 (br m, 1H), 3.32 (s, 3H), 3.68 (m, 2H), 3.93 (m, 6H), 5.34 (d, 1H,
J=4.5 Hz). HRMS: (C34H60NO) Calcd 498.8463, found 498.4734. Anal.
(C34H60NOBr) Calcd. C, 70.56; H,10.45; N, 2.42; found. C, 70.35; H, 10.17;
N, 2.15.
Chol–DABCO. 1H-NMR (CDCl3,300 MHz):δ 0.64 (s, 3H), 0.82–2.3
(m, 40H), 3.21 (br t, 7H), 3.77 (t, 6H), 3.93 (br s, 4H), 5.34 (d, 1H, J=4.5 Hz).
HRMS: (C35H61N2O) Calcd. 525.8717; found 525.4899. Anal. (C35H61N2OBr)
Calcd. C, 69.39; H,10.15; N, 4.62; found. C, 69.50; H, 10.47; N, 4.54.
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(m, 40H), 3.08 (br m, 1H), 3.23 (t, 6H), 3.86 (s, 2H), 4.60 (s, 2H), 5.29 (d, 1H,
J=4.5 Hz), 6.83 (d, 2H), 8.60 (d, 2H). HRMS (C36H59N2O): Calcd. 535.4627,
found 535.4622. Anal. (C36H59N2OBr.H2O) Calcd. C, 68.22; H, 9.70; N, 4.42;
found. C, 68.12; H, 9.61; N, 4.34.
Chol–NMe. 1H-NMR (CDCl3, 300 MHz):δ 0.64 (s, 3H), 0.82–2.3 (m, 40H),
3.18 (br m, 1H), 3.47 (br. s, 11H), 3.92 (t, 2H, J=6.0 Hz), 5.33(d, 1H, J=4.5 Hz).
HRMS (C32H58NO): Calcd. 472.8091; found 472.4456. Anal. (C32H58NOBr)
Calcd. C, 69.54; H, 10.58; N, 2.53, found. C, 69.29; H, 10.51; N, 2.76.
Synthesis of Chol–PR. Cholest-5-en-3β-oxyethane bromide (5) (60 mg,
0.12 mmol) was taken in dry MeOH: EtOAc (4 ml, v/v: 1/1) in a screw-top
pressure tube. N-methyl piperazine (27.33 mg, 0.30 mmol) was added to this
solution and the resulting solution was refluxed for 24 h. After that, the reaction
mixture was cooled and the solvent was evaporated. Crude reaction mixture was
dissolved in CHCl3 (50 ml) and washed with water (50 ml), followed by brine
(saturated NaCl) and dried over anhydrous Na2SO4. Organic layer was eva-
porated and compound was purified by column chromatography over silica gel
using a mixture of petroleum ether and ethyl acetate [v/v=10:1]. 1H-NMR
(CDCl3, 300 MHz,):δ 0.60 (s, 3H), 0.78–2.3 (m, 40H), 2.44–2.54 (br m, 13H),
3.08 (br m, 1H), 3.55 (t, 2H, J=6.0 Hz) 5.27 (d, 1H, J=4.5 Hz). HRMS:
(C34H60N2O+H
+) Calcd. 513.4784, found 513.4783. Anal. (C34H60N2O)
Calcd. C, 79.63; H,11.79; N, 5.46; found C, 79.42; H,11.54; N, 5.67.
Synthesis of 7. In a round bottom flask, N-methyl piperazine (6) (100 mg,
1.11 mmol) was taken in THF (5 ml). 134 mg of Et3N (0.18 ml,1.33 mmol)
was added to it and the reaction mixture was stirred for 15 min at room
temperature. To this solution, BOC-anhydride (314 mg, 1.44 mmol) was added
and the reaction mixture was further stirred for 6 h at room temperature.
Reaction was followed by TLC and continued till the full consumption of N-
methyl piperazine. After that, the solvent was removed under vacuum. Crude
reaction mixture was dissolved in CHCl3 (50 ml) and washed with water
(20 ml), 1 N HCl (2×20 ml), water (20 ml), saturated NaHCO3 (20 ml), water
(20 ml), followed by brine (saturated NaCl) (20 ml) and dried over anhydrous
Na2SO4. The product was obtained as a solid mass upon passing through silica
gel column with petroleum ether followed by CHCl3. The isolated yield was:
90%. IR (neat) (cm−1). 1700. 1H-NMR (CDCl3, 300 MHz):δ 1.32 (s, 9H), 2.19
(s, 3H), 2.22 (t, 4H), 3.30 (t, 4H).
Synthesis of 8. Cholest-5-en-3β-oxyethane bromide (5) (60 mg, 0.12 mmol)
was taken in dry MeOH: EtOAc (4 ml, v/v: 1/1) in a screw-top pressure tube.
To this, 7 (60 mg, 0.3 mmol) was added and the resulting solution was refluxed
for 72 h. After that reaction mixture was cooled and solvent was evaporated.
Resulting mixture was purified by repeated crystallization from a mixture
of MeOH: EtOAc. Yield: 80%, 67.5 mg, 0.097 mmol, 1H-NMR (CDCl3,
300 MHz):δ 0.64 (s, 3H), 0.82–2.31 (br m, 53H), 3.18 (br m, 1H), 3.53 (s, 3H),
3.75 (br m, 4H), 3.97 (br s, 2H), 4.18 (br m, 2H), 5.33 (d, 1H, J=4.5 Hz).
ESI–MS: 614.0 (M+).
Chol–PR+. Compound 8 (65 mg, 0.093 mmol) was taken in MeOH (6 ml).
2 ml of 1 N HCl was added to the solution and the resulting solution was stirred
for 4 h at room temperature. Reaction was followed till TLC indicated the
complete disappearance of 8. Product was purified by repeated EtOAc washing
followed by drying. The yield was quantitative. 1H-NMR (300 MHz, CDCl3):δ
0.65 (s, 3H), 0.83–2.32 (m, 40H), 2.8 (br m, 1H), 3.12–3.32 (m, 6H), 3.54–3.9
(br m, 7H), 5.27 (d, 1H, J=4.5 Hz). HRMS: (C31H64N2O) Calcd 513.4784,
found 513.4938. Anal. (C31H64N2OBr) Calcd. C, 68.78; H, 10.35; N, 4.72,
found C, 68.57, H, 10.07, N, 4.53.
2.2. Preparation of lipid suspensions
Individual lipid (∼0.5 mg) was dissolved in chloroform in autoclaved
Wheaton glass vials. Thin films were made by evaporation of the organic solvent
under a steady stream of dry nitrogen. Last traces of organic solvent were
removed by keeping these films under vacuum overnight. Freshly autoclaved
water (Milli-Q) was added to individual film such that the final concentration of
the cationic lipid was 0.5 mM. The mixtures were kept for hydration at 4 °C for
10–12 h and were repeatedly freeze–thawed (ice-cold water to 70 °C) with
intermittent vortexing to ensure hydration. Sonication of these suspensions for
15 min in a bath sonicator at 70 °C afforded aggregates. Liposomes were
prepared and kept under sterile conditions. Formulations were stable and if stored
frozen, possessed long shelf-life.2.3. Preparation of lipid:DOPE mixed liposomes
Lipid (0.5 mg) and DOPE in desired mole ratios were taken in chloroform in
autoclaved Wheaton glass vials. Thin films were made by evaporation of the
organic solvent under a steady stream of dry nitrogen. Hydrated films were
repeatedly freeze–thawed (ice-cold water to 70 °C) with intermittent vortexing
to ensure hydration. Sonication of these suspensions for 15 min in a bath soni-
cator at 70 °C afforded aggregates.
2.4. Dynamic light scattering
Unilamellar vesicles (1 mM) were prepared in pure water (Millipore) as
mentioned under vesicle preparation. They were diluted to 0.33 mM and were
used for dynamic light scattering measurements. Experiments were performed
using a DynaPro molecular sizing instrument, which employed an incident laser
beam of∼830 nmwavelength. An interfaced autocorrelator was used to generate
the full auto-correlation of the scattered intensity. The time-correlated function
was analyzed by the method of cumulants and calculations yielded specific
distribution of particle size populations. The values reported are the averages of
two independent experiments, each of them having 10 sub-runs.
2.5. Plasmid DNA
pEGFP-c3 (Clontech, USA), which encodes for an enhanced green fluo-
rescence protein (GFP) under a CMV promoter, was amplified in Escherichia coli
(DH5α) and purified using Qiagen Midi Prep Plasmid Purification protocol
(Qiagen, Germany). Purity of the plasmidwas checked by electrophoresis on 1.0%
agarose gel. Concentration of the DNAwas estimated spectroscopically by mea-
suring the absorption at 260 nm and confirmed by gel electrophoresis. The plasmid
preparations showing a value of OD260/OD280N1.8 were used.
2.6. Cell culture
Cells (HeLa) were cultured in Dulbecco'sModified Eagle'sMedium (DMEM;
Sigma) supplemented with 10% fetal bovine serum (FBS) in T25 culture flasks
(Nunc, Denmark) and were incubated at 37 °C in a humidified atmosphere con-
taining 5%CO2. Cells were regularly passaged by trypsinizationwith 0.1% trypsin
(EDTA 0.02%, dextrose 0.05%, and trypsin 0.1%) in PBS (pH 7.2).
2.7. Cytotoxicity
Toxicity of each cationic lipid formulation towards HeLa cells in the pre-
sence of 10% FBS was determined using 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide reduction assay following literature procedures
[55,56]. Nearly 15,000 cells/well were plated in 96 well plate. After 24 h,
optimized lipid/DOPE formulations were complexed with 0.2 μg of the DNA at
various N/P ratios for 30 min. Lipid–DNA complexes were added to the cells in
the absence of serum. After 6 h of incubation, lipoplexes were removed and
200 μl of media with 10% FBS was added. After 42 h, 20 μl of MTT solution
was added and the cells were incubated further for 4 h. Blue formazan crystals
were seen at well when checked under microscope. Media were removed and
200 μl of DMSO was added per well. The absorbance was measured using a
microtiter plate reader. The % viability was then calculated as [{A590(treated
cells)-background] / [A590(Untreated cells)-background}]×100.
2.8. Transfection procedure
All transfection experiments were carried out in HeLa cells in antibiotic-free
media unless specified otherwise. In a typical experiment, 24-well plates were
seeded with 60,000 cells/well in antibiotic-free media 24 h before trans-
fection such that they were at least ∼70% confluent at the time of transfection.
For transfection, lipid formulation and DNA were serially diluted separately in
DMEMcontaining no serum to have the required working stocks. DNAwas used
at a concentration of 0.8 μg/well unless specified otherwise. The lipid and DNA
were complexed in a volume of 200 μl by incubating the desired amount of lipid
formulation and DNA together at room temperature for about 30 min. The lipid
concentrations were varied so as to obtain the required lipid/DNA (N/P) charge
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to nucleotide base molarity and were calculated by considering the average
nucleotide mass of 330. After 30 min of complexation, 200 μl of media were
added to the complexes (final DNA concentration=12.12 μM). Old mediumwas
removed from the wells, cells were washed with DMEM and lipid–DNA com-
plexes in 200 μl media were added to the cells. The plates were then incubated for
6 h at 37 °C in a humidified atmosphere containing 5% CO2. At the end of the
incubation period, medium was removed and cells were washed with DMEM,
500 μl of DMEM containing 10% FBS was added per well. Plates were further
incubated for a period of 42 h before checking for the reporter gene expression.
GFP expression was examined by fluorescence microscopy and was quantified
by flow cytometry analysis.
For transfections in the presence of serum, lipid and DNA were separately
diluted in serum-freemedia as alreadymentioned and the complexationwas done
in serum-free media (200 μl) for 30 min. The complex was then diluted to 400 μl
with DMEM containing 20% FBS so as to achieve a final serum concentration of
10%. The cells were then incubated with these complexes for 6 h. At the end of
the incubation period,mediumwas removed and cells werewashedwith DMEM,
500 μl of DMEM containing 10% FBS was added per well.
2.9. Gel electrophoresis
To examine the complexation of DNA with cationic lipid suspensions at
different lipid–DNA (N/P) ratios, we prepared lipid–DNA (N/P) complexes at
different lipid–DNA charge (N/P) ratios in an identical manner as was done with
transfection experiments. After 30 min of incubation, these complexes were
electrophoretically run on a 1.0% agarose gel. The uncomplexed DNA moved
out of well but the DNA that was complexed with lipid remained inside the well
[57].
2.10. Flow cytometry
The reporter gene expression was examined by fluorescence microscopy at
regular intervals and was quantified 48 h post transfection by flow cytometry.
Percentage of transfected cells were obtained by determining the statistics of
cells fluorescing above the control level wherein non-transfected cells were used
as the control. Approximately, 10,000 cells were analyzed to achieve the sta-
tistical data, which have been presented as the average of at least two indepen-
dent measurements. For flow cytometry analysis, ∼48 h post transfection, old
medium was removed from the wells; cells were washed with PBS and
trypsinized by adding 100 μl of 0.1% trypsin. To each well 200 μl of PBS
containing 20% FBS was added. Duplicate cultures were pooled and analyzed
by flow cytometry immediately using Becton and Dickinson flow cytometer
equipped with a fixed laser source at 488 nm.
2.11. FACS analysis
FACS data were analyzed by public domain WinMDI software to eliminate
data from cell debris (particles smaller than cells), dead cells, and clumps of 2 or
more cells [58]. Subcellular debris and clumps can be distinguished from single
cells by size (estimated by the intensity of low angle forward-scatter). Dead cells
have lower forward-scatter and higher side-scatter than living cells [58]. The
FACS scans have been configured to display the fluorescence signals only from
those particles with a specified set of scatter properties, namely, living single
cells. This is called a scatter-gated fluorescence analysis. Therefore the data from
dead cells were eliminated by gating out brightly fluorescent cells.
2.12. Ethidium bromide intercalation assay
Fluorescence emission due to ethidium bromide (EB) at 592 nm was
monitored in a Hitachi model F-4500 spectrofluorimeter (λex=526 nm with
10 nm slit widths for both excitation and emission). Typically emission was
measured for EB (25 μM) in 5 mM HEPES, 0.1 M NaCl, pH 7.4 buffer. To this
CT-DNA (40 μM) was added and again emission due to EB upon intercalative
complexation with DNA was measured at 37 °C. Then an aliquot of a given
liposome (2 μM) was added into preformed EB/CT–DNA complex in 5 mM
HEPES (pH 7.4) buffer. This resulted in a fluorescence quenching due to thedisplacement of EB molecules from intercalated sites caused due to distortion in
DNA double-helix upon addition of cationic lipid aggregates. Progressive ad-
dition of SDS (2 μM) aliquot (below cmc of SDS) to preformed cationic lipid/
DNA complex resulted in the release of DNA from cationic lipid/DNA complex.
Due to release of DNA, EB gets reintercalated and fluorescence emission
increases. If F0 is the fluorescence intensity (FI) of unintercalated and Fmax is
the FI of fully intercalated EB, and Fx is the FI for a given concentration of
liposome or SDS, % FI=(Fx−F0)/(Fmax−F0).
3. Results
3.1. Synthesis
Eight cholesterol based cationic lipids have been synthe-
sized where the cholesterol backbone is linked to different
cationic headgroups via an ether type linkage. Cholesterol
tosylate (2) was synthesized by tosylation of cholesterol (1)
using p-toluenesulfonyl chloride in pyridine-chloroform (v/v:
1/1) in the presence of a catalytic amount of DMAP for 6 h at
0 °C in 92% yield (Scheme 1). Cholesterol tosylate (2) was then
subjected to a reaction with ethylene glycol in dioxane under
reflux for 4 h to afford cholest-5-en-3β-oxyethan-2-ol (3) in
85% yield, which was then tosylated with p-toluenesulfonyl
chloride in pyridine-chloroform (v/v: 1/1) for 6 h at 0 °C to get
4 in 90% yield. Reaction of the tosylate (4) with LiBr in dry
DMF at 70 °C, afforded the precursor 5 in 82% yields. Catio-
nic lipids have been synthesized by reaction of the bromide
(5) with corresponding amine in 80–90% yields. All the catio-
nic lipids have been purified by repeated crystallizations from
MeOH and EtOAc. Cationic lipid Chol–PR was synthesized by
N-alkylation of N-methyl piperazine in a sealed tube (Scheme 2).
For the synthesis of cationic lipid Chol–PR+, firstly secondary
amine of the N-methyl piperazine (6) was protected by t-BOC
group (Scheme 2). Then the resulting monoprotected ter-
tiary amine (7) upon further reaction with bromide (5) afforded
compound 8 in quantitative yield (Scheme 2). Deprotection of
the t-BOC group from 8 yields the Chol–PR+ in quantitative
yields. All the cationic lipids were characterized by 1H-NMR,
HRMS and elemental analysis as described in the experimental
section.
3.2. Characterization of neat lipid suspensions
Lipid suspensionswere prepared by repeatedly freeze–thawing
(ice-cold water to 70 °C) the hydrated lipids with intermit-
tent vortexing. The aggregates were prepared by sonicating
these lipid suspensions in a bath sonicator at 70 °C for 15 min.
All lipids were found to get dispersed in water easily and
formed stable suspensions in water. No precipitation or noti-
ceable increase in turbidity was observed even after one month
when suspensions were stored at 4 °C under sterile condi-
tions. The suspensions formed from each lipid were opti-
cally clearer. Neat lipid suspensions were characterized by
dynamic light scattering. Table 1 shows the hydrodynamic
diameter of the neat lipid suspensions obtained from dynamic
light scattering experiments. Chol–PR+ lipid suspensions were
largest in size whereas Chol–DABCO lipid suspensions were
smallest in size.
Scheme 1. Reaction conditions: (a) p-TsCl/Py/CHCl3, 0 °C, 6 h; (b) ethylene glycol, 1,4-dioxane, 4 h, reflux; (c) p-TsCl/Py/CHCl3, 0 °C, 6 h; (d) LiBr, DMF, 70 °C,
6 h; (e) MeOH–EtOAc, appropriate amine, 80 °C, screw-top pressure tube, 48 h.
1227A. Bajaj et al. / Biochimica et Biophysica Acta 1778 (2008) 1222–12363.3. Characterization of lipid:DOPE mixed liposomes
After characterizing neat lipid suspensions, co-liposomal
formulations from lipid:DOPE (1:1) mixtures were character-
ized, as DOPE is known to enhance the gene transfection effi-
cacies of cationic lipid based formulations. Lipid:DOPE (1:1)
mixtures were able to form stable liposomes by first subjecting
them to freeze–thaw cycles followed by sonication in aqueous
media. Hydrodynamic diameter of lipid suspensions decreased
upon incorporation of DOPE in case of all lipid:DOPE co-
liposomal suspensions except in case of Chol–DABCO and
Chol–MOR (Table 1).
4. Transfection biology
4.1. Optimization of lipid:DOPE ratio
Natural lipid DOPE is well known to enhance the trans-
fection efficacy of cationic lipid based formulations. Opti-
mized lipid:DOPE formulation for DNA complexation oftendepends on the molecular structure of the cationic lipids.
Accordingly, we carried out transfection experiments by
varying the mole ratios of the cationic lipids in DOPE and
the lipids alone at N/P ratio of 1.0 using EGFP-c3 plasmid
DNA in HeLa cells. Most of the cationic lipids were found to
show maximum transfection at lipid:DOPE mole ratio of 1:1
(Fig. 3), whereas lipid Chol–DMAP and Chol–PR formula-
tions showed maximum transfection efficacy when used
without DOPE. Incorporation of the DOPE does not enhance
the transfection activity significantly in these liposome
formulations. Cationic lipid, Chol–PR+ was found to show
maximum transfection activity at lipid:DOPE mole ratios of
1:0.5–1:1.
4.2. Optimization of N/P ratio
The lipid–DNA complexes were then subjected to gene de-
livery assays at different N/P ratios using optimized lipid:DOPE
formulations. The percentage of GFP cells observed by FACS
analysis at different N/P ratios for all cationic lipid formulations
Scheme 2. Reaction conditions: (a) 5, MeOH/EtOAc (1:1), 80 °C, screw-top sealed tube, 24 h; (b) (BOC)2, THF, Et3N, rt, 5 h; (c) 5, MeOH/EtOAc (1:1), 80 °C, screw-
top sealed tube, 24 h; (d) 5 N HCl, MeOH, rt, 2 h.
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showed nearly 60% transfection activity at N/P ratio of 3 and 4
by FACS analysis (Fig. 4). In case of lipid Chol–NMP and
Chol–PYR, more than 70% cells were found to be GFP positive
by FACS analysis at N/P ratio of 3 and 4. At low N/P ratios,
for Chol–NMP and Chol–PYR, the transfection efficacy was
very low. In contrast Chol–NMe and Chol–DMAP formulations
showed nearly 80% transfection activity at N/P ratio of 3.0
(Fig. 4). In these cases, Chol–NMe lipid was used as 1:1 co-
liposomal formulation of lipid and DOPE, whereas in case of
Chol–DMAP formulation, no DOPE was used. Chol–PR and
Chol–PR+ formulations, showed nearly 40–50% GFP positive
cells by FACS analysis.Table 1
Hydrodynamic diameters of lipid aggregates obtained from DLS measurements
Neat lipid suspensions Lipid:DOPE (1:1) suspensions
Lipid Size (nm) a Size (nm) a
Chol–NMe 194 100
Chol–DABCO 104 105
Chol–DMAP 173 91
Chol–MOR 131 184
Chol–NMP 230 168
Chol–PYR 128 118
Chol–PR 171 96
Chol–PR+ 249 148
a Hydrodynamic diameters obtained from DLS measurements.4.3. Transfection in the presence of serum
One of the major drawbacks of the cationic liposomal me-
diated gene delivery, especially involving in vivo trials, is the
poor efficacy of such formulations in the presence of serum
proteins. The negatively charged serum proteins compete with
lipid–DNA complexes, thereby reducing the efficacy of lipo-
somal formulations significantly. Transfections in the absence
of serum even for in vitro experiments are also burdensome
due to the increased toxicity of the synthetic cationic lipid
formulations.
To see the effect of the serum on the gene transfection
efficacies of these newly synthesized cationic lipids with
different headgroups, we carried out the transfection experi-
ments in the presence of 10% serum conditions at different
N/P ratios using optimized lipid:DOPE formulations (Fig. 5).
Only 20% cells were found to be GFP positive by FACS
analysis in case of lipid formulations Chol–DABCO and
Chol–MOR, whereas in case of Chol–NMP formulation
nearly 35% cells were found to be positive (Fig. 5). At N/P
ratio of 1.0, only 20% positive cells were found in case of
Chol–NMe formulation, but at higher N/P ratios nearly 55%
cells got transfected as observed by FACS analysis (Fig. 5).
To our pleasant surprise, Chol–DMAP formulations which
was used without DOPE, showed nearly 75% transfection
efficacy at N/P ratio of 3.0. Lipid formulations Chol–PR and
Chol–PR+ showed 40–45% transfection efficacy. Fig. 6
shows the comparative transfection activities of different
Fig. 3. Transfection efficiencies of cholesterol based cationic lipids with various mole ratios of DOPE. (a) Chol–DABCO; (b) Chol–MOR; (c) Chol–NMP; (d) Chol–
PYR; (e) Chol–NMe; (f) Chol–DMAP; (g) Chol–PR; (h) Chol–PR+. Concentration of the DNA=0.8 μg/well and lipid were used at N/P ratio of 1.0. Lipoplexes were
incubated with cells for 6 h. Data are expressed as number of transfected cells.
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presence of serum, which clearly indicates that Chol–DMAP
formulation is the most effective transfecting nearly 60% of
the cells in the presence of serum. Nearly 40–45% cells were
found to be positive in case of cationic lipid formulations
Chol–NMe, Chol–PR and Chol–PR+, whereas in case of theother formulations, only 10–20% transfection activity was
observed. The major advantage of the Chol–DMAP formula-
tions is that there is no need for the DOPE for the formulation,
whereas most of the commercially available cationic lipid
formulations are the mixtures of cationic lipid and DOPE at
different mole ratios.
Fig. 4. Transfection efficiencies of cholesterol based cationic lipids using optimized lipid:DOPE formulations at various N/P ratios in the absence of serum (-FBS−
FBS). (a) Chol–DABCO; (b) Chol–MOR; (c) Chol–NMP; (d) Chol–PYR; (e) Chol–NMe; (f) Chol–DMAP; (g) Chol–PR; (h) Chol–PR+. Concentration of the
DNA=0.8 μg/well. Lipoplexes were incubated with cells for 6 h. Data are expressed as number of transfected cells.
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The lipid–DNA complexes were then subjected to MTT
assays at different N/P ratios using optimized lipid:DOPE for-mulations (Fig. 7). In case of lipid Chol–NMP and Chol–PYR,
where more than 70% cells were found to be GFP positive by
FACS analysis at N/P ratio of 3 and 4 but these formulations
were found to be highly toxic as only 60% cells were found to
Fig. 5. Transfection efficiencies of cholesterol based cationic lipids using optimized lipid:DOPE formulations at various N/P ratios in the presence of 10% serum (-FBS+
FBS). (a) Chol–DABCO; (b) Chol–MOR; (c) Chol–NMP; (d) Chol–PYR; (e) Chol–NMe; (f) Chol–DMAP; (g) Chol–PR; (h) Chol–PR+. Concentration of the
DNA=0.8 μg/well. Lipoplexes were incubated with cells for 6 h. Data are expressed as number of transfected cells.
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and Chol–PYR where the cell viabilities were found to be high,
low transfection efficiency was observed. In contrast Chol–
NMe and Chol–DMAP formulations showed nearly 80%transfection activity with minimal cytotoxicity at N/P ratio of
3.0. Chol–PR+ lipid–DNA complexes were found to be highly
toxic as compared to Chol–PR at N/P ratio of 4.0. Only 50%
cell viability was found at N/P ratio of 4.0 in case of Chol–PR+
Fig. 6. Comparative transfection efficiencies of cationic lipids in the absence (-FBS−FBS) and presence of 10% serum (-FBS+FBS) at N/P ratio of 2.0. Concentration
of the DNA=0.8 μg/well. Lipoplexes were incubated with cells for 6 h. Data are expressed as number of transfected cells.
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was found. The above results indicate that the introduction of
the cationic headgroup increases the cell toxicity of the cationic
lipid formulations.
5. Characterization of lipid–DNA complexes
5.1. Gel electrophoresis
Generally, cationic amphiphiles bind to anions efficiently
[59]. Similarly these liposomes containing cationic lipids also
bind to DNA via ion pairing. To find out the effect of the head-Fig. 7. Cytotoxicity exhibited toward HeLa cells by lipoplexes at different N/P
ratios using optimized lipid/DOPE formulations. All the experiments were
performed in triplicates in 96-well plates. Concentration of the DNA=0.2 μg/well.
Lipoplexeswere incubatedwith cells for 6 h. The%viability was then calculated as
[{A590(treated cells)-background] / [A590(untreated cells)-background}]×100.group on the DNA binding efficiencies, we carried out con-
ventional gel electrophoresis at different N/P ratios (Fig. 8).
Among all cationic lipid formulations, Chol–NMe and Chol–
DABCO were found to be highly efficient in DNA binding as
more than 90% of the plasmid DNAwas found to get retarded at
N/P ratio of 1.0. More than 90% of the DNA was retarded in
case of Chol–DMAP lipid formulation at N/P ratio of 2.0. In
case of other formulations except Chol–PR+, no movement of
plasmid DNA from the well was observed at N/P ratio of 2.0.
Chol–PR+ formulation was found to be least effective in DNA
binding as at even N/P ratio of 4.0 there was hardly any change
in movement of the plasmid DNA.
5.2. DNA complexation by cationic liposomes
To probe the lipoplex formation, fluorescence experiments
were performed by exposing ds-DNA molecules to ethidium
bromide (EB), which acts as a fluorescent probe via intercalation
with the DNA base pairs. Progressive addition of a given ca-
tionic liposome into the EB/CT–DNA complex led to a gradual
quenching of the EB fluorescence emission eventually leading
to saturation. Quenching of the fluorescence intensity (FI) at
592 nm upon addition of cationic liposomes is due to the gradual
release of free EB out of the EB/CT–DNA complex. This could
be explained on the basis of the cationic liposome induced
compaction formation of DNA,which facilitates the dissociation
of EB from the EB–DNA complex. The percentage decreases of
FI (FI%) till saturation for given liposomeswere found to depend
on the molecular structure of the cationic lipid. Fig. 9 shows how
various cationic lipid suspensions promote dissociation of EB
from EB–DNA complexes.
Formulations based on Chol–PR and Chol–PR+ were found
to be the least efficient in ethidium bromide exclusion, libe-
rating only 40% ethidium bromide from the DNA–ethidium
complexes. Lipid Chol–NMe formulation was found to displace
maximum ethidium bromide from DNA complexes, displacing
nearly 70% at N/P ratio of 2–3, whereas other lipid formulations
induced ∼50% dissociation of EB. This value is plotted as the
percentage decrease in FI as shown in Fig. 9. The % decrease in
Fig. 8. Electrophoretic gel patterns for lipoplex-associated DNA in gel retardation for cationic cholesterol lipids. The N/P ratios are indicated at the top of each lane.
0.2 μg of the DNA was complexed with liposomes at various N/P ratios for 30 min and lipoplexes were run electrophoretically on 1% agarose gel.
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some complex. This also reflects the ability of the given cationic
liposome to complex with DNA. However, the ability of a lipidFig. 9. Release of the ethidium bromide (EB) from the DNA–EB complexes
upon addition of the liposomes at different lipid/DNA charge ratios.aggregate to attain saturation appeared to be related to the lipid
molecular structure. It indicates that the binding of the lipo-
somes depends on cationic head group. Lipids bearing trimethyl
ammonium headgroup (Chol–NMe) bind strongly as compared
to other lipid formulations, whereas Chol–PR and Chol–PR+
were found to be the weakest in DNA binding.
5.3. SDS-induced release of DNA from cationic liposome–DNA
complexes
Endosomal layers of the cell, which are rich in the negatively
charged lipids are believed to facilitate the DNA release from its
complexes with cationic liposomes. We have used negatively
charged SDS micelles to induce release of DNA from various
cationic liposome–DNA complexes. An aqueous solution of
EB (25 μM) gave a broad λmax at 592 nm when excited at
526 nm. In the presence of CT-DNA (40 μM base molarity) the
FI at 592 nm due to intercalated EB increased more than 5-fold.
Addition of an aqueous solution of a given cationic liposome to
the EB/DNA complex resulted in quenching of the FI as dis-
cussed previously. Progressive addition of SDS triggers dis-
sociation of cationic lipids from the cationic liposome/DNA
complex. This in turn facilitates the re-intercalation of EB into
CT-DNA that gets released from the lipoplex. The increase in
the fluorescence intensity reached a plateau at a particular con-
centration of SDS for a given cationic liposome/DNA complex.
Beyond this concentration further addition of SDS did not result
in any additional extent of fluorescence recovery as shown in
Fig. 10.
Examination of the profiles obtained by SDS promoted the
DNA release from a given cationic liposome/DNA complex
Fig. 10. Re-intercalation of the ethidium bromide (EB) to the DNA upon the
release of the DNA from lipid/DNA complexes after the addition of SDS at
different SDS/lipid charge ratios.
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required to reach saturation value of FI was not the same for
different cationic liposome/DNA complexes. The complexes of
liposomal Chol–DABCOwith DNA showed∼90% recovery of
FI at SDS/lipid charge ratio of 0.5–0.6, but this formulation did
not bind DNA very efficiently as shown by ethidium bromide
exclusion assay. Chol–NMe based formulation, which was
found to be most effective in DNA binding, showed nearly
∼70% recovery at charge ratio of 1.0 and similarly in case of
Chol–DMAP ∼70% recovery at charge ratio of 1.0. Chol–PR
and Chol–PR+ formulations showed high (70–75%) recovery,
but these formulations were found to be weak in DNA binding as
evidenced from ethidium bromide exclusion assay. Chol–MOR
and Chol–PYR release the DNA easily upon addition of SDS as
these formulations were also found to be less efficient in binding.
6. Discussion
Gene delivery has progressed significantly because of the
considerable development of the cationic lipids in the last few
years. Various biological barriers for the efficient delivery of
nucleic acids into the target cells have been identified till now
[60,61]. Systematic modifications at different parts of the ca-
tionic lipids have been incorporated to find out the molecular
level insights into the transfection activities of the cationic lipidsof a given class. Different kinds of the hydrophobic backbones,
linkages and the headgroups have been developed for efficient
gene delivery.
To get further progress in this direction, we prepared dif-
ferent cationic lipids based on different headgroups possessing
ether linkage between the headgroup and the cholesterol back-
bone [53,54]. Different headgroups based on cyclic aliphatic or
aromatic rings, heteroatom substituted cyclic rings were con-
sidered. Although synthetically more demanding, ether func-
tionality has been introduced between the headgroup and the
cholesterol backbone [53,54]. All the lipids were found to be
form stable suspensions neat as well as with DOPE [62].
All the lipids were used for transfection studies in HeLa cells.
Helper lipid DOPE is known to enhance the cationic lipid me-
diated gene delivery [48,49]. Therefore, all cationic lipid:DOPE
ratioswere firstly optimized for transfection studies. Among these
cationic lipids, Chol–DMAP having one pyridinium group and a
tertiary amine was found to show efficient transfections even in
the absence of DOPE. Similarly, Chol–PR cationic lipid, which
has two tertiary amine functionalities showed optimized transfec-
tion without use of DOPE as well. These structural elements may
be useful for further design of gene carrier vectors, where the
necessity of the use of DOPE can be eliminated. To bring the
cationic liposomemediated gene delivery into clinical trials, there
is need for the serum compatible cationic lipids. Chol–DMAP
lipid was found to be the highly efficient in the presence of serum
conditions, where as in other formulations there was dramatic
reduction in the efficacy of transfection mediated by cationic
lipids in the presence of serum. Cationic lipids are known to
inhibit the protein kinaseC activity, making them too toxic to cells
[63]. Comparison of the cell viabilities of the Chol–PR and Chol–
PR+ showed that the introduction of the positive charge reduced
the cell viabilities.
In order to explain the possible basis of the differential
transfection activity of the lipids, we have performed ethidium
bromide exclusion assay of cationic lipid formulations with
calf-thymus DNA (CT-DNA) to gain an insight into the nature
of interactions. Effect of the addition of different positively
charged liposomes to CT-DNA were examined using ethidium
bromide as staining probe [64,65]. Ethidium bromide exclusion
and SDS-induced release of DNA from lipid–DNA complexes
assays were performed to get insights into the different trans-
fection activities of the cationic lipids. Although the fluores-
cence quenching was seen in all the instances, there were
significant differences in the minimum concentration (c) of the
liposomes required for inducing saturation in the fluorescence
quenching. Molecular level modifications in the headgroup
structure influenced the binding of the liposomes with DNA.
Chol–NMe lipid based liposomes were found to bind strongly
with DNA, replacing maximum ethidium bromide from the
DNA as compared to other lipid based liposomes. As compared
to Chol–NMe, all other cationic lipids possessing cyclic head-
groups were found to be not suitable for efficient binding to
DNA as the cationic charge is probably masked in the cyclic
moiety. Thus Chol–PR and Chol–PR+ liposomal formulations
were found to be least efficient both in the DNA binding abi-
lities as well as transfection activities.
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several steps and the mechanism of many of these steps are not
clear at the molecular level, [60,61] it would be important to
note some correlation between the molecular structures of these
new cationic lipids, and the transfection efficiencies. Whatever
may be the actual mechanism for transfection mediated by this
class of lipid formulations, the meaningful results obtained with
these new cholesterol based cationic lipids should be of interest
to researchers working in the field of gene therapy using non-
viral vectors.
In summary, we have shown that the transfection efficacies
of the ether linked cholesterol based cationic lipids depend
strongly on the nature of the head group. The transfection in the
presence of serum was also found to depend strongly upon the
type of headgroup. As the changes in the headgroup region
brings the different effects on the aggregation properties of the
cationic lipids, this factor further influences the transfection
properties of the resulting cationic lipid suspensions.
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